Septerna, Inc. - SEPN Net Assets per Single Share

Graphic logo of Septerna Inc (SEPN)

Septerna Inc (SEPN) specializes in developing GPCR receptor drugs, facing challenges such as a lack of profitability and dependence on external capital. Business growth relies on successes in treating endocrine pathologies and a strong scientific team, with the current figure standing at 8.53. The historical price action is presented below, complementing data on the flawless operation of robotic laboratories and the stable functioning of R&D centers.

Septerna, Inc. (SEPN): Share Book Value from 10/26/2024 to 10/26/2026

septerna.com - analytical breakdowns and key metrics (SEPN)

- price and consensus price forecast:
Price Chart Septerna Corp|SEPN - Forecast Levels Chart
- market capitalization data:
Market Value Septerna Inc|SEPN - Business Value
- book capitalization data:
Net Assets per Single Share Septerna|SEPN - Net Asset Value|Market Capitalization to Book Value Ratio septerna.com|SEPN - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Septerna Inc|SEPN - Long-Term Debt to Capital|Short-Term Debt to Equity Septerna|SEPN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Septerna Inc
Fundamental company valuation:Septerna Corp - SEPN
Manufactured products of Septerna

Book value per share determines the portion of equity attributable to a single security upon the liquidation of all liabilities. By analyzing the trend in book value per share, an investor assesses the issuer's actual tangible asset base. The metric is calculated as the difference between assets and liabilities divided by the number of shares. For Septerna Inc (SEPN), this metric reflects the volume of investment in early-stage drug development. Capital growth here confirms the capitalization of intellectual property within the endocrinology sector.

Competitors of Septerna Inc (SEPN)

Net Assets per Single Share Argenx|BNTX: Share Book Value|Net Assets per Single Share Abivax Corp|ADMA (admabiologics.com) - Equity per Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Kiniksa Pharmaceuticals Ltd (KNSA) - Book Value per Share|Accounting Value of a Share Grifols Biemat (GRFS)|Book Value per Share ADPT (Adaptive Biotechnologies)|celldex.com - Book Value per Share|Net Assets per Single Share Aurinia Pharmaceuticals Inc. (AUPH)|BCRX: Accounting Value of a Share|VERA (Vera Pharma) - Net Assets per Single Share|Dianthus Corp (DNTH) - Accounting Value per Share|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp (ABCL)|Tourmaline Bio (TRML) - Accounting Value per Share|Accounting Value of a Share Precigen Inc (PGEN)|Book Value per Share PHAR|Nektar Corp - Net Assets per Share|UPB: Net Assets per Single Share|ZBIO: Accounting Value per Share|IMNM (Immunome) - Net Assets per Single Share|Accounting Value per Share Gossamer Bio Inc|KALV (KalVista Pharmaceuticals Inc) - Accounting Value per Share|Book Value per Share PVLA|Net Assets per Single Share Savara Inc. SVRA|Equity per Share rigel.com (RIGL)|ANAB: Book Value per Share|Astria Therapeutics Inc - Net Asset Value per Share|Net Assets per Single Share ENGN (enGene Bio)|RAPT - Net Assets per Share|Book Value per Share JBIO|ACRS (aclaristx.com) - Net Asset Value per Share|Net Assets per Single Share Kyverna Therapeutics, Inc. KYTX|Share Book Value Tiziana Life Sciences Ltd. (TLSA)|Accounting Value per Share Cabaletta Bio, Inc|Book Price of a Share Ventyx Biosciences, Inc (VTYX)|THTX: Book Value per Share|avalotx.com - Net Asset Value per Share|Net Assets per Single Share Eledon Pharmaceuticals, Inc. (ELDN)|AGEN: Accounting Value of a Share|Net Assets per Single Share Climb Bio, Inc.|Zura Bio Ltd (ZURA) - Equity per Share|ATYR (aTyr Pharma, Inc.) - Book Value per Share|Book Value per Share Adagene Corp (ADAG)|ImageneBio Inc (IMA) - Accounting Value per Share|Accounting Value of a Share shattucklabs.com (STTK)|Book Value per Share EQ|Connect Biopharma Holdings - Net Assets per Share|Immunic Inc (IMUX) - Net Assets per Single Share|ATRA - Equity per Share|IFRX (inflarx.de) - Book Value per Share|XFOR (X4 Pharmaceuticals Inc.) - Accounting Value per Share|ACET: Net Assets per Single Share|Net Assets per Share Celularity Corp|INmune Bio, Inc. - Book Value per Share|Net Asset Value per Share BRNS (barinthusbio.com)|Kezar Life Sciences, Inc. (KZR) - Net Assets per Single Share|SAB Biotherapeutics Inc. - Share Book Value|Akari Therapeutics plc (AKTX) - Net Assets per Single Share|ENLV: Equity per Share|Net Assets per Single Share q32bio.com (QTTB)|geovax.com (GOVX) - Share Book Value|EDSA - Book Value per Share|Accounting Value of a Share iBio Inc|Book Value per Share CARM|Book Value per Share XTLB (XTL Bio)|Net Assets per Single Share Bolt Biotherapeutics, Inc.|HCW Biologics, Inc. - Accounting Value of a Share|APVO: Net Assets per Single Share|AIM - Accounting Value per Share|ADTX: Book Value per Share|Book Value per Share GRI Bio Corporation|XRTX - Accounting Value per Share|Accounting Value of a Share reshapelifesciences.com|REVB (Revelation Biosciences, Inc.) - Book Value per Share|Net Assets per Share INDP (Indaptus Therapeutics Inc)|Scinai - Net Assets per Single Share|CalciMedica Inc - Accounting Value per Share|AFMD: Net Assets per Single Share|Allakos Inc. (ALLK) - Accounting Value per Share|HOOK: Accounting Value per Share|IGMS (IGM Biosciences) - Book Value per Share|Net Assets per Single Share iTeos (ITOS)|Equity per Share Ocean Biomedical Corp|TC Biopharm - Book Value per Share|Net Asset Value per Share THRD (thirdharmonicbio.com)